#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

The CAROLINA study and its impact on clinical practice


Authors: Paclíková M.
Authors‘ workplace: III. interní klinika FN Hradec Králové
Published in: Kardiol Rev Int Med 2019, 21(4): 194-198

Overview

The CAROLINA Study confirmed the long-term CV safety profile of linagliptin relative to glimepirid in patients with early T2DM at increased CV risk. To ensure optimal CV benefit for patients with T2DM and CV dis­ease, contemporary guidelienes prefer that SGL2 inhibitors or GLP-1 analogs with proven CV benefit be added to metformin, or drugs with proved cardiovascular safety such as DPP-4 inhibitors.

Keywords:

CAROLINA study – linagliptin – cardiovascular safety


Sources

1. Einarson TR, Acs A, Ludwig C et al. Prevalence of cardiovascular dis­ease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007– 2017. Cardiovasc Diabetol 2018; 17(1): 83. doi: 10.1186/ s12933-018-0728-6.

2. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes and mortality in type 2diabetes. N Engl J Med 2015; 373(22): 2117– 2128. doi: 10.1056/ NEJMoa1504720.

3. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin, cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644– 657. doi: 10.1056/ NEJMoa1611925.

4. Wiviott S, Raz I, Bonaca MP et al. Dapagliflozin and cardiovacular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347– 357. doi: 10.1056/ NEJMoa1812389.

5. Marso S, Daniels GH, Brown-Frandsen K et al. Liraglutid and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311– 322. doi: 10.1056/ NEJMoa1603827.

6. Davies MJ, D’Alessio DA, Fradkin J et al. Management of hyperglycemia for type 2 diabetes, 2018. A consensus report by ADA/ EASD. Diabetes Care 2018. doi: 10.2337/ dci18-0033. Available at: https:/ / care.diabetesjournals.org/ content/ early/ 2018/ 09/ 27/ dci18-0033.

7. Škrha J. Diabetologie. Praha: Galén 2009.

8. Rosolová H, Pelikánová T, Moťovská Z. Doporučené postupy ESC týkající se diabetu a prediabetu a kardiovaskulárních onemocnění ve spolupráci s EASD. Cor Vasa 2014; 56(2): e190– e205. doi: 10.1016/ j.crvasa.2014.01.007.

9. Meinert CL, Knatterud GL, Prout TE et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 (Suppl): 789–830.10. Pelikánová T, Bartoš V a kol. Praktická diabetologie. 6. vyd. Praha: Maxdorf 2018.

11. Trajenta (lnagliptin). Summary of product characteristics (Boehringer-Ingelheim, August 2019). Available at: https:/ / www.medicines.org.uk/ emc/ product/ 4762/ smpc.

12. Rosenstock J, Kahn SE, Johansen O et al. Effect of linagliptin vs glimepirid on major adverse cardiovascular otcomes i patients with type 2 diabetes the CAROLINA randomized clinical trial. JAMA 2019; 322(12): 1155– 1166. doi: 10.1001/ jaa.2019.13772.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#